Evaluating the effects of oligopin supplementation on the turnover of bone formation and antioxidant changes in postmenopausal osteopenic wome

Phase 3

• Conditions: Osteopenia.; Postmenopausal osteoporosis; M 81.0

• Registration Number: IRCT2017060334308N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 44

Inclusion Criteria

Postmenopausal women;
Aged between 50-65;
Diagnosis of osteopenia based on Tscore ( -2.5 SD = Tscore = -1 SD)
To have equal physical, pediatric and complementary therapies for at least three months before entrance to study

Exclusion Criteria

The subjects were excluded if they had body mass index = 40 kg/m2, the occurrence of any visible side effects of the intervention,fracture report during the follow-up period, refusal to continue the trial, history of bone disorders, history of any malignancy, diabetes, kidney failure, hepatic disease, skeletal disorders, systemic inflammatory diseases, rheumatologic disorders, degenerative joint diseases, hyperthyroidism, Cushing's syndrome, history of gastrointestinal disease or bleeding, motor disabilities, untreated psychiatric illnesses such as Alzheimer's disease, Parkinson's disease, psychosis, and current smoking and alcohol intake.As for the history of the use of drugs, women receiving osteoporosis drugs (e.g. estrogen receptor-selective agonists / antagonists, bisphosphonates, PTH, and alternative HRTs), anticonvulsants (i.e. phenobarbital, phenytoin, sodium valproate), nonsteroidal anti-inflammatory drugs (i.e. naproxen, aspirin, and ibuprofen), thiazides, diuretics, glucocorticoids were not permitted to participate in this study.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Carboxy terminal collagen type I. Timepoint: Before and third month after intervention. Method of measurement: ELISA.;Osteocalcin. Timepoint: Before and third month after intervention. Method of measurement: ELISA.;Osteocalcin/CTX1 ratio. Timepoint: Before and third month after interventio. Method of measurement: --.